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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Lithuanian 
language. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical vali-
dation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 101 JIA patients (5.9% systemic, 38.6% oligoarticular, 23.8% RF negative 
polyarthritis, 31.7% other categories) and 116 healthy children, were enrolled at the paediatric rheumatology centre in Vilnius. 
The JAMAR components discriminated well healthy subjects from JIA patients. Notably, there is no significant difference 
between healthy subjects and their affected peers in the school-related problems variable. All JAMAR components revealed 
good psychometric performances. In conclusion, the Lithuanian version of the JAMAR is a valid tool for the assessment of 
children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Lithuanian parent, child/adult version of 
the Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Lithuanian language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from January 2012 to 
September 2012. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL), PF-hand 
and wrist (PF -HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
items-scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should 
be lower than their reliability coefficients, as measured 
by Cronbach’s alpha); test–retest reliability or intraclass 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in 
its two components: the convergent or external validity 
which examines the correlation of the JAMAR subscales 
with the six JIA core set variables, with the addition of 
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the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the dis-
criminant validity, which assesses whether the JAMAR 
discriminates between the different JIA categories and 
healthy children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Lithuanian parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Lithuanian JAMAR was fully cross-culturally adapted 
with two forward and two backward translations with a 
concordance for 117/123 translations lines (95.1%) for the 
parent version and 116/120 lines (96.7%) for the child ver-
sion. In the probe technique analysis, all the 123 lines of 
the parent version of the JAMAR were understood by at 
least 80% of the 10 parents tested (median 100%; range 
80–100%). In the patient version of the JAMAR, 113/120 
(94.2%) lines were understood by at least 80% of the chil-
dren (median 100%; range 70–100%). The text of the par-
ent JAMAR was unmodified after the probe technique; lines 
62, 63, 64, 66, 67, 68, and 69 were modified according to 
patients’ suggestions.
Demographic and clinical characteristics 
of the subjects
A total of 101 JIA patients and 116 healthy children (total 
of 217 subjects) were enrolled at the paediatric rheumatol-
ogy centre.
In the 101 JIA subjects, the JIA categories were 5.9% with 
systemic arthritis, 38.6% with oligoarthritis, 23.8% with RF 
negative polyarthritis, 1.0% with RF positive polyarthritis, 
14.8% with psoriatic arthritis, 14.8% with enthesitis-related 
arthritis and 1.0% with undifferentiated arthritis (Table 1).
A total of 116/217 (53.5%) subjects had the parent ver-
sion of the JAMAR completed by a parent (101 from parents 
of JIA patients and 15 from parents of healthy children). The 
JAMAR was completed by 101/116 (87.1%) mothers and 
15/116 (12.9%) fathers. The child version of the JAMAR 
was completed by 170/217 (78.3%) children age 7.3 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there is no signif-
icant difference between healthy subjects and their affected 
peers in the school-related problems variable.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
except for item 8, whereas a reduced number of response 
choices were used for PF items 6, 9, 10, 11, 13, and 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items (data 
not shown). The median number of items marked as not 
applicable was 0% (0–1.0%) for the PF and 2.0% (0–3.0%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 81.2% (56.4–88.1%) for the 
PF items, 43.6% (19.8–50.5%) for the HRQoL-PhH items, 
and 39.6% (29.7–48.5%) for the HRQoL-PsH items. The 
median ceiling effect was 2.0% (0.0–5.0%) for the PF 
items, 5.9% (4.0–8.9%) for the HRQoL-PhH items, and 
4.0% (2.0–4.0%) for the HRQoL-PsH items. The median 
floor effect was 15.8% for the pain VAS, 13.9% for the 
disease activity VAS and 13.9% for the well-being VAS. 
The median ceiling effect was 2.0% for the pain VAS, 
2.0% for the disease activity VAS and 1.0% for the well-
being VAS.
Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap 
were roughly equivalent for items within a scale for 93% 
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 101 JIA patients
Systemic 
(N = 6)
Oligoarthri-
tis (N = 39)
RF− pol-
yarthritis 
(N = 24)
RF + pol-
yarthritis 
(N = 1)
Psoriatic 
arthritis 
(N = 15)
Enthesitis-
related 
arthritis 
(N = 15)
Undifferenti-
ated arthritis 
(N = 1)
All JIA 
patients 
(N = 101)
Healthy 
(N = 116)
Female 3 (50%) 30 (76.9%) 21 (87.5%) 1 (100%) 12 (80%) 3 (20%) 1 (100%) 71 (70.3%)* 67 (57.8%)
Age at visit 10.7 
(9.6–12)
6.9 (4.5–12) 13.8 
(9.4–14.8)
9 (9–9) 15.1 
(9.9–16.7)
14.2 (12.7–
16.5)
3 (3–3) 12 (7.5–
14.8)#
15.8 (14–
16.4)#
Age at onset 6.6 (3.1–10) 4.1 (2.1–7.9) 5.9 (3.1–
10.9)
8.8 (8.8–8.8) 10.8 (8–14) 10 (8.9–
13.7)
2.9 (2.9–2.9) 7.4 (3.1–
10.9)*
Disease 
duration
1.6 (0.4–7) 2 (1.1–4.5) 4.5 (1.7–9.2) 0.1 (0.1–0.1) 3.2 (0.9–6.6) 2.8 (0.6–4.8) 0.1 (0.1–0.1) 2.8 (0.9–5.4)
ESR 57.5 (12–85) 6.5 (4–18) 7.5 (4–36) (-) 10 (2–15) 5 (2–15) (-) 8 (4–20)
MD VAS 
(0–10 cm)
5.5 (4–8) 4 (2–5) 2 (1–5) 7 (7–7) 3 (1–6) 3 (2–5) 3 (3–3) 3 (2–5)
No. swollen 
joints
3.5 (2–32) 2 (1–3) 0 (0–12.5) 8 (8–8) 1 (0–8) 2 (0–3) 1 (1–1) 2 (0–5)
No. joints 
with pain
5.5 (3–34) 2 (1–5) 4.5 (2–14.5) 8 (8–8) 5 (4–14) 3 (1–7) 1 (1–1) 3 (1–8)
No. joints 
with LOM
10.5 (3–32) 2 (1–5) 8.5 (2–22.5) 8 (8–8) 4 (2–8) 3 (1–5) 0 (0–0) 3 (1–8)
No. active 
joints
5 (3–32) 2 (1–4) 4.5 (2–15) 8 (8–8) 4 (1–8) 3 (1–5) 1 (1–1) 3 (1–6)
Active 
systemic 
features
3 (50%) 0 (0%) 1 (4.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (4%)*
ANA status 0 (0%) 1 (2.6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Uveitis 0 (0%) 2 (5.1%) 0 (0%) 0 (0%) 1 (6.7%) 0 (0%) 1 (100%) 4 (4%)
PF total 
score
8 (0–14) 2 (0–6) 4 (2–10) 6 (6–6) 5 (3–10) 4 (0–6) 1 (1–1) 3 (1–7) 0 (0–0)#
Pain VAS 6.5 (5.5–8) 3 (0.5–5) 3.5 (0.8–5.5) 3.5 (3.5–3.5) 4 (3–8) 5 (2–7) 2 (2–2) 3.5 (1–6.5) 0 (0–0)#
Disease 
activity 
VAS
7 (5–7) 3 (0.5–7) 4.5 (1.3–6) 3 (3–3) 2 (1–6) 3 (2–5) 3.5 (3.5–3.5) 3.5 (1–6.5)
Well-being 
VAS
5.3 (5–6) 2 (0.5–5) 2.5 (0.8–5.3) 4 (4–4) 4 (1–7) 3 (1–4.5) 1 (1–1) 3 (1–5)
HRQoL-PhH 4.5 (4–5) 2 (1–6) 4.5 (3–6.5) 10 (10–10) 5 (2–8) 4 (2–7) 1 (1–1) 4 (2–6)* 0 (0–0)#
HRQoL-PsH 2.5 (2–5) 3 (1–5) 3 (2–4.5) 3 (3–3) 4 (2–5) 2 (1–4) 1 (1–1) 3 (2–5) 0 (0–1)#
HRQoL total 
score
8.5 (6–11) 6 (2–11) 8.5 (5–11.5) 15 (15–15) 10 (6–12) 6 (3–12) 2 (2–2) 6 (4–11) 0 (0–1)#
Pain/swell. 
in > 1 joint
6 (100%) 33 (84.6%) 20 (83.3%) 1 (100%) 12 (80%) 14 (93.3%) 1 (100%) 87 (86.1%) 0 (0%)#
Morning 
stiff-
ness > 15 
minutes
5 (83.3%) 13 (33.3%) 11 (45.8%) 0 (0%) 7 (46.7%) 7 (46.7%) 0 (0%) 43 (42.6%) 0 (0%)**
Subjective 
remission
6 (100%) 28 (71.8%) 19 (79.2%) 1 (100%) 10 (66.7%) 12 (80%) 1 (100%) 77 (76.2%)
In treatment 6 (100%) 36 (92.3%) 23 (95.8%) 1 (100%) 14 (93.3%) 13 (86.7%) 0 (0%) 93 (92.1%)
Reporting 
side effects
1 (16.7%) 6 (16.7%) 8 (34.8%) 1 (100%) 0 (0%) 4 (30.8%) 20 (21.5%)
Taking 
medication 
regularly
6 (100%) 36/36 
(100%)
23/23 
(100%)
1 (100%) 14/14 
(100%)
13/13 
(100%)
93/93 
(100%)
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of the PF items, with the exception of PF item 15, and for 
100% of the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 93% of 
items of the PF (except for PF item 15) and 100% of items 
of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.93 for PF-LL, 0.92 for PF-HW, 
0.82 for PF-US. Cronbach’s alpha was 0.81 for HRQoL-
PhH and 0.80 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha, 
except for the PF item 13.
Test–retest reliability
Reliability was assessed in six JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 0 days (0–0 day). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC 1.0). The ICC for the HRQoL-PhH and 
for the HRQoL-PsH showed an almost perfect reproducibil-
ity (ICC 1.0 and ICC 0.99, respectively).
Convergent validity
The Spearman correlation of the PF total score with the JIA 
core set of outcome variables ranged from 0.4 to 0.6 (median 
0.5). The PF total score best correlation was observed with 
the parent assessment of pain (r = 0.6, p < 0.001). For the 
HRQoL, the median correlation of the PhH with the JIA core 
set of outcome variables ranged from 0.5 to 0.6 (median 0.5), 
whereas for the PsH ranged from 0.2 to 0.4 (median 0.4). The 
PhH showed the best correlation with the parent global assess-
ment of well-being (r = 0.6, p < 0.001) and the PsH with the 
parent’s assessment of pain (r = 0.4, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centred and labora-
tory measures were 0.5 (0.3–0.5), 0.5 (0.4–0.5), 0.4 (0.3–0.5), 
respectively.
Discussion
In this study, the Lithuanian version of the JAMAR was 
cross-culturally adapted from the original standard English 
version with two forward and two backward translations. 
According to the results of the validation analysis, the Lithu-
anian parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-specific 
components of the questionnaire discriminated well between 
patients with JIA and healthy controls. Notably, there is no 
Data related to the JAMAR refers to the 101 JIA patients and to the 15 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity; 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH Psychosocial Health (total score ranges from 0 to 15).
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Table 1  (continued)
Systemic 
(N = 6)
Oligoarthri-
tis (N = 39)
RF− pol-
yarthritis 
(N = 24)
RF + pol-
yarthritis 
(N = 1)
Psoriatic 
arthritis 
(N = 15)
Enthesitis-
related 
arthritis 
(N = 15)
Undifferenti-
ated arthritis 
(N = 1)
All JIA 
patients 
(N = 101)
Healthy 
(N = 116)
With 
problems 
attending 
school
0 (0%) 0 (0%) 2/15 (13.3%) 1 (100%) 1/7 (14.3%) 2/11 (18.2%) 6/53 
(11.3%)
0 (0%)
Satisfied 
with 
disease 
outcome
1 (16.7%) 20 (51.3%) 12 (50%) 0 (0%) 7 (46.7%) 5 (33.3%) 0 (0%) 45 (44.6%)
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significant difference between the healthy subjects and their 
affected peers in the school-related problems variable. This 
finding indicates that children with JIA adapt well to the 
consequences of JIA, and have school performances com-
parable to those of their healthy peers.
Psychometric evaluation was good for all domains with 
few exceptions: PF item 15 (bite a sandwich or an apple) 
shows a lower items internal consistency. However, the over-
all internal consistency was excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters were moderate.
The statistical performances of the child version of the 
JAMAR are very similar, even though somewhat poorer, to 
those obtained by the parent version, which suggests that 
children are reliable reporters of their disease and health 
status.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 101/116) Child (N = 69/170)
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 81.2% 81.2%
 HRQoL-PhH 43.6% 44.9%
 HRQoL-PsH 39.6% 53.6%
 Pain VAS 15.8% 14.5%
 Disease activity VAS 13.9% 17.4%
 Well-being VAS 13.9% 18.8%
Ceiling effect, median
 PF 2.0% 0.0%
 HRQoL-PhH 5.9% 5.8%
 HRQoL-PsH 4.0% 4.3%
 Pain VAS 2.0% 0.0%
 Disease activity VAS 2.0% 0.0%
 Well-being VAS 1.0% 0.0%
Items with equivalent item–scale correlation 93% for PF, 100% for HRQoL 67% for PF, 80% for HRQoL
Items with items–scale correlation ≥ 0.4 93% for PF, 100% for HRQoL 67% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.93 0.77
 PF-HW 0.92 0.73
 PF-US 0.82 0.53
 HRQoL-PhH 0.81 0.84
 HRQoL-PsH 0.80 0.77
Items with item–scale correlation lower than the Cronbach’s alpha 93% for PF, 100% for HRQoL 87% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 1.0 0.95
 HRQoL-PhH 1.0 1.0
 HRQoL-PsH 0.99 1.0
Spearman correlation with JIA core set variables, median
 PF 0.5 0.5
 HRQoL-PhH 0.5 0.5
 HRQoL-PsH 0.4 0.3
 Pain VAS 0.5 0.4
 Disease activity VAS 0.5 0.4
 Well-being VAS 0.4 0.5
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The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care. In conclusion, 
the Lithuanian version of the JAMAR was found to have 
satisfactory psychometric properties and it is, thus, a reli-
able and valid tool for the multidimensional assessment of 
children with JIA.
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